請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/31175
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳為堅(Wei J. Chen) | |
dc.contributor.author | Hsuan-Yu Chen | en |
dc.contributor.author | 陳璿宇 | zh_TW |
dc.date.accessioned | 2021-06-13T02:33:57Z | - |
dc.date.available | 2008-01-11 | |
dc.date.copyright | 2007-02-02 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-01-23 | |
dc.identifier.citation | 1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. European Journal of Cancer 2001;37:S4-66. 3. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355:479-85. 4. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7. 5. Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988;96:440-7. 6. Ludwig JA, Weinstein JN. Biomarkers in Cancer Staging, Prognosis and Treatment Selection. Nat Rev Cancer 2005;5:845-56. 7. Sidransky D. EMERGING MOLECULAR MARKERS OF CANCER. Nat Rev Cancer 2002;2:210-9. 8. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends. J Natl Cancer Inst 2002;94:981-90. 9. Vastag B. Study Concludes That Moderate PSA Levels Are Unrelated to Prostate Cancer Outcomes. JAMA 2002;287:969-70. 10. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69. 11. Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev 2006;16:4-9. 12. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006;66:7390-4. 13. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-31. 14. Schena M, Shalon D, Davis RW, Brown PO. Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray. Science 1995;270:467-70. 15. Schena M, Shalon D, Heller R, Chai A, Brown PO, Davis RW. Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci U S A 1996;93:10614-9. 16. Hoheisel JD. Microarray technology: beyond transcript profiling and genotype analysis. Nat Rev Genet 2006;7:200-10. 17. Golub TR, Slonim DK, Tamayo P, et al. Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring. Science 1999;286:531-7. 18. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54. 19. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24. 20. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001;98:13790-5. 21. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001;98:13784-9. 22. Wigle DA, Jurisica I, Radulovich N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 2002;62:3005-8. 23. Gordon GJ, Jensen RV, Hsiao L-L, et al. Translation of Microarray Data into Clinically Relevant Cancer Diagnostic Tests Using Gene Expression Ratios in Lung Cancer and Mesothelioma. Cancer Res 2002;62:4963-7. 24. Ramaswamy S. Translating Cancer Genomics into Clinical Oncology. N Engl J Med 2004;350:1814-6. 25. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes. N Engl J Med 2004;350:1828-37. 26. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61. 27. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia. N Engl J Med 2005;353:1793-801. 28. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70. 29. Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors Are Associated With Distinctive Pathologic Features and Clinical Behavior. J Clin Oncol 2006. 30. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-6. 31. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98. 32. Endoh H, Tomida S, Yatabe Y, et al. Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol 2004;22:811-9. 33. Chen JJ, Peck K, Hong TM, et al. Global analysis of gene expression in invasion by a lung cancer model. Cancer Res 2001;61:5223-30. 34. Shih JY, Yang SC, Hong TM, et al. Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J Natl Cancer Inst 2001;93:1392-400. 35. Tsai M-F, Wang C-C, Chang G-C, et al. A New Tumor Suppressor DnaJ-like Heat Shock Protein, HLJ1, and Survival of Patients With Non-Small-Cell Lung Carcinoma. J Natl Cancer Inst 2006;98:825-38. 36. Wang C-C, Tsai M-F, Hong T-M, et al. The transcriptional factor YY1 upregulates the novel invasion suppressor HLJ1 expression and inhibits cancer cell invasion. Oncogene 2005;24:4081-93. 37. Chen JJ, Wu R, Yang PC, et al. Profiling expression patterns and isolating differentially expressed genes by cDNA microarray system with colorimetry detection. Genomics 1998;51:313-24. 38. Chen JJ, Lin YC, Yao PL, et al. Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 2005;23:953-64. 39. Bieche I, Onody P, Laurendeau I, et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999;45:1148-56. 40. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93. 41. Cox DR. Regression Models and Life-Tables. Journal of the Royal Statistical Society Series B 1972;34:187-220. 42. Koziol JA, Zhang J-Y, Casiano CA, et al. Recursive Partitioning as an Approach to Selection of Immune Markers for Tumor Diagnosis. Clin Cancer Res 2003;9:5120-6. 43. Zhang H, Yu C-Y, Singer B, Xiong M. Recursive partitioning for tumor classification with gene expression microarray data. Proc Natl Acad Sci U S A 2001;98:6730-5. 44. AvadisTM. AvadisTM user manual. USA: Strand Genomic Pvt Ltd; 2004. 45. Shafer JC, Agrawal R, Mehta: M. SPRINT: A Scalable Parallel Classifier for Data Mining. In: Proc of the 22th Int'l Conference on Very Large Databases; 1996; India; 1996. 46. Bast RC, Jr., Hortobagyi GN. Individualized Care for Patients with Cancer -- A Work in Progress. N Engl J Med 2004;351:2865-7. 47. The International Adjuvant Lung Cancer Trial Collaborative G. Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer. N Engl J Med 2004;350:351-60. 48. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 1997;278:1630-2. 49. Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004;4:97-105. 50. Rehli M, Krause SW, Schwarzfischer L, Kreutz M, Andreesen R. Molecular cloning of a novel macrophage maturation-associated transcript encoding a protein with several potential transmembrane domains. Biochem Biophys Res Commun 1995;217:661-7. 51. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 2003;162:1807-15. 52. Muller-Tidow C, Diederichs S, Bulk E, et al. Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res 2005;65:1778-82. 53. Zamoyska R, Basson A, Filby A, Legname G, Lovatt M, Seddon B. The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation. Immunol Rev 2003;191:107-18. 54. Mahabeleshwar GH, Das R, Kundu GC. Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways. J Biol Chem 2004;279:9733-42. 55. Mahabeleshwar GH, Kundu GC. Tyrosine kinase p56lck regulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of IkappaBalpha following hypoxia/reoxygenation. J Biol Chem 2003;278:52598-612. 56. Miller YE. Pathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol 2005;33:216-23. 57. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80. 58. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66. 59. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 2005;33:5394-403. 60. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8. 61. Olaussen KA, Dunant A, Fouret P, et al. DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy. N Engl J Med 2006;355:983-91. 62. Czech MP. MicroRNAs as therapeutic targets. N Engl J Med 2006;354:1194-5. 63. Grosshans H, Johnson T, Reinert KL, Gerstein M, Slack FJ. The temporal patterning microRNA let-7 regulates several transcription factors at the larval to adult transition in C. elegans. Dev Cell 2005;8:321-30. 64. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-47. 65. Felli N, Fontana L, Pelosi E, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A 2005;102:18081-6. 66. Poliseno L, Tuccoli A, Mariani L, et al. MicroRNAs modulate the angiogenic properties of HUVEC. Blood 2006. 67. Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006;124:1169-81. 68. Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet 2005;37:495-500. 69. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115:787-98. 70. Hsu PW, Huang HD, Hsu SD, et al. miRNAMap: genomic maps of microRNA genes and their target genes in mammalian genomes. Nucleic Acids Res 2006;34:D135-9. 71. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006;34:D140-4. 72. Liu CC, Lin CC, Chen WS, et al. CRSD: a comprehensive web server for composite regulatory signature discovery. Nucleic Acids Res 2006;34:W571-7. 73. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005;102:19075-80. 74. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004. 75. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the Use of DNA Microarray Data for Diagnostic and Prognostic Classification. J Natl Cancer Inst 2003;95:14-8. 76. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the Odds Ratio in Gauging the Performance of a Diagnostic, Prognostic, or Screening Marker. Am J Epidemiol 2004;159:882-90. 77. Ware JH. The Limitations of Risk Factors as Prognostic Tools. N Engl J Med 2006;355:2615-7. 78. Wang TJ, Gona P, Larson MG, et al. Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death. N Engl J Med 2006;355:2631-9. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/31175 | - |
dc.description.abstract | 現行臨床分期系統無法準確地預測非小細胞肺癌病人的存活與復發情形,本研究利用微陣列技術以及即時反轉錄聚合酶連鎖反應兩種測量基因表現的方法,探討基因表現剖繪以及微小核醣核酸和非小細胞肺癌病人臨床結果的關係。本研究主要為兩部份,第一部份為利用基因表現預測非小細胞肺癌病人存活與復發,第二部份為微小核醣核酸 (microRNA)在非小細胞肺癌的預後上的應用。
研究一、利用基因表現剖繪預測非小細胞肺癌的臨床結果 背景:利用基因表現預測非小細胞肺癌病人的存活準確性較目前的臨床分期方法佳,在現有研究的結果中,由於需利用幾十或上百個基因才能達到準確預測的目的。本研究擬建立只利用少數基因表現的預測方法,將其應用至非小細胞肺癌病人的預後。方法:利用微陣列晶片 (microarray)以及即時反轉錄聚合酶連鎖 (real time RT-PCR)反應方法測量125個臨床肺癌檢體的基因表現,以及進行基因表現與存活資料的相關分析。最後利用風險分數 (risk score)與決策樹 (decision tree)分析方法建立基因表現預測模式,以此模式預測肺癌病人的存活與復發。除了原來的125檢體外,另外將此預測模式套用至另外的60個肺癌檢體以及來自國外已發表的資料中86個肺癌病人資料,以驗證此預測模式。結果:利用微陣列晶片與風險分數方法找出與臨床存活有關的16個基因,其中5個基因在RT-PCR與微陣列實驗結果相近,這5個基因分別為(DUSP6、MMD、STAT1、 ERBB3以及LCK)。接著利用此五個基因建立決策樹分析模式,以此模式能預測高風險的病人校正後的風險對比值為2.82倍 (95% 信賴區間: 1.38-5.78)。在另外的60個檢體的驗證資料中,預測的高風險的病人其風險對比值為3.36倍 (95% 信賴區間: 1.35-8.35),在國外發表的資料中也有得到顯著的結果(風險對比值4.36倍,95% 信賴區間: 1.01-18.76)。結論:以此五個基因表現建構的預測模式,能準確地預測非小細胞肺癌病人的存活。 研究二、微小核甘核酸與非小細胞肺癌的臨床結果 背景:微小核甘核酸為一群新發現的核甘核酸,其不會轉譯成蛋白質而且能負向調構基因表現。本研究擬建立利用微小核甘核酸表現的預測方法,探討其與非小細胞肺癌病人預後的相關。方法:利用即時反轉錄聚合酶連鎖 (real time RT-PCR)反應方法測量112個臨床肺癌檢體的微小核甘核酸表現,以及進行基因表現與存活資料的相關分析。最後利用風險分數分析方法建立微小核甘核酸表現預測模式,以此模式預測肺癌病人的存活與復發。最後利用另一家醫學中心的62個肺癌檢體,驗證此風險分數預測模式。結果:5個微小核甘核酸與病人存活有關,分別為(hsa-let-7a、 hsa-miR-221、hsa-miR-137、hsa-miR-372和hsa-miR-182*),利用此五個基因建構風險分數預測模式,以此模式預測肺癌病人的存活與復發的風險。以病人死亡情形來說,在原始資料中的訓練組56個病人,高風險的病人的風險對比值為10.31倍 (95% 信賴區間: 2.33-45.56);驗證組56個病人中高風險的病人的校正風險對比值為3.65倍 (95% 信賴區間: 1.29-10.37);在另一家醫學中心的62個檢體的驗證資料中,預測的高風險的病人其校正風險對比值為2.81倍 (95% 信賴區間: 1.13-7.01)。以病人復發情形來說,在原始的訓練組56個病人中,高風險的病人的校正風險對比值為3.29倍 (95% 信賴區間: 1.24-8.71);驗證組56個病人中高風險的病人的校正風險對比值為2.86倍 (95% 信賴區間: 1.20-6.82);在另一家醫學中心的62個檢體的驗證資料中,預測的高風險的病人其校正風險對比值為2.39倍 (95% 信賴區間: 1.12-5.10)。分層分析的結果顯示,不論是一期、二期、三期肺癌,或是肺癌癌與鱗狀細胞癌等不同細胞形態等分層中,此五微小核甘核酸預測模式能準確預測病人的存活與復發。結論:五個微小核甘核酸建構的預測模式,能準確地預測非小細胞肺癌病人的存活與復發,並能提供肺癌病人後續治療的參考。 本研究利用基因印記預測病人的存活與復發,包括五個基因表現所建構的模式以及五個微小核醣核酸的預測模式,皆能準確預測肺癌病人的存活與復發。未來需要前瞻性的大規模追蹤試驗,用足夠的樣本數目檢驗本研究的發現。 | zh_TW |
dc.description.abstract | Current clinical staging system can not accurately predict patients’ outcome. In this study, microarray technology and real time RT-PCR were carried out to assay the gene expressions, including gene expression profile and microRNA signature. This disser- tation included two studies of non-small-cell lung cancer. One is “Gene Expression Signature Predicts Clinical Outcomes in NSCLC” and another is “microRNA Expre- ssion Profile and Clinical Outcomes in NSCLC”.
Study 1: Gene Expression Signature Predicts Clinical Outcomes in NSCLC Background: Using molecular profiling approach to predict patients’ outcome is better than current staging method. of non-small cell lung carcinoma (NSCLC). In this study, a model based on few number of gene will be established and predicted survival in NSCLC. Methods: Gene expression in surgical specimens of 125 samples of surgi- cally resected NSCLC was studied by microarray and real-time reverse transcriptase polymerase chain reaction (RT-PCR), and the results were compared with survival. We used the risk score and decision tree methods to develop a gene-expression model to predict the outcome of NSCLC. The results were validated in an independent cohort from 60 patients and published dataset from 86 samples. Results: Sixteen genes that correlated with survival in patients with NSCLC were identified using microarray and risk score analysis. We selected 5 genes (DUSP6, MMD, STAT1, ERBB3 and LCK) and developed a risk predictive model based on RT-PCR and a decision tree analysis. The 5-gene signature is an independent predictor of cancer recurrence and overall survival of NSCLC patients (hazard ratio [HR] =2.82, 95% CI= 1.38-5.78). We validated the model in an independent cohort of 60 NSCLC patients (HR=3.36, 95% CI= 1.35-8.35) and in a set of published microarray data of 86 patients (HR=4.36, 95% CI= 1.01-18.76). Conclusions: A 5-gene signature can predict survival and relapse of NSCLC patients. Study 2: microRNA Expression Profile and Clinical Outcomes in NSCLC Background: MicroRNAs are a new class of small non-protein-coding RNAs that function as endogenous negative gene-regulators and can act as oncogenes or tumor- suppressors. An microRNA signature will be developed and significantly associated with survival of NSCLC patients. Methods: Using real-time reverse transcriptase polymerase chain reaction (RT-PCR), we studied microRNA expression in tumor-specimens of 112 patients who had undergone surgical resection of NSCLC. Results were correlated with patients’ survival. We used Cox regression and risk-score analysis to develop a microRNA signature for the prediction of treatment outcome of NSCLC. Results: We identified a 5- microRNA signature (hsa-let-7a, hsa-miR-221, hsa-miR-137, hsa-miR-372 and hsa-miR -182*) associated with survival of 56 NSCLC patients each in the training and testing sets. We reconfirmed the findings in an independent cohort of 62 NSCLC patients. NSCLC pa- tients with high-expression of the 5-microRNA signature had reduced overall survival (adjusted HR=2.81, 95%CI=1.13-7.01, p=0.026) and disease-free survival (adjusted HR= 2.39, 95%CI=1.12-5.10, p=0.024) compared to low-expression patients, even after stratify- ing patients by stage I, II, III, adenocarcinoma or squamous cell carcinoma subgroups. The 5-microRNA signature was more effective to predict survival of NSCLC patients compared to less-than-five or single-microRNA signatures (p<0.05, log-rank tests).Conclusions: An unique microRNA signature can predict cancer relapse and survival of NSCLC patients. MicroRNAs may have implications in molecular-pathogenesis of NSCLC, selection of high-risk patients for adjuvant chemotherapy or development of new targeted-therapy for NSCLC. In conclusion, our results indicate that using a gene signature composed of relatively small number of genes, either a five-gene or 5-microRNA signature, can predict the recurrence as well as overall survival of NSCLC and further validation of these findings in a prospective cohort of large sample size is warranted. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T02:33:57Z (GMT). No. of bitstreams: 1 ntu-96-D92842001-1.pdf: 1507545 bytes, checksum: 9ea7e4ada65a1571f96ba0b2a3e60864 (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 中文摘要 …………………………………………………………… I
ABSTACT …………………………………………………………… IV LIST OF FIGURES …………………………………………………………… IX LIST OF TABLES …………………………………………………………… X CHAPTER 1 Introduction……………………………………………… 1 CHAPTER 2 Study 1: Gene Expression Signature Predicts Clinical Outcomes in NSCLC ………………………………. 5 2.1 Introduction …………………………………………………………… 5 2.2 Methods …………………………………………………………… 6 2.2.1 Patients and Tissue Specimens …………………………. 6 2.2.2 cDNA Microarray Analysis ……………………………... 6 2.2.3 Real-Time RT-PCR Analysis …………………………… 7 2.2.4 Statistical Analysis ……………………………………… 7 2.3 Results …………………………………………………………… 11 2.3.1 A 16-Gene Microarray Signature and Survival and Metastasis in NSCLC …………………………………… 11 2.3.2 5-Gene Signature by Real-Time RT-PCR Correlates with Survivals of 101 NSCLC Patients ……………………… 12 2.3.3 Validation of the 5-Gene Signature ……………………... 13 2.3.4 Validation of the 5-Gene Signature in a Set of published Microarray Data ………………………………………… 14 2.4 Discussion …………………………………………………………… 14 CHAPTER 3 Study 2: microRNA Expression Profile and Clinical Outcomes in NSCLC ………………………………….. 27 3.1 Introduction …………………………………………………………… 27 3.2 Methods …………………………………………………………… 28 3.2.1 Patients and Tissue Specimens …………………………. 28 3.2.2 MicroRNA Profiling ……………………………………. 28 3.2.3 Statistical Analysis ……………………………………… 29 3.3 Results …………………………………………………………… 30 3.4 Discussion …………………………………………………………… 32 CHAPTER 4 Conclusion and Future Perspective ……………………... 49 REFERENCES …………………………………………………………… 51 APPENDIX …………………………………………………………… 62 | |
dc.language.iso | en | |
dc.title | 非小細胞肺癌之基因印記:基因表現剖繪與微小核醣核酸在臨床預後之應用 | zh_TW |
dc.title | Gene Signature in Non-Small-Cell Lung Cancer: Application of Gene Expression Profile and MicroRNA in Clinical Outcome | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-1 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 楊泮池(Pan-Chyr Yang) | |
dc.contributor.oralexamcommittee | 陳健尉(Jian-Wei Chen),陳君厚(Chun-houh Chen),李文宗(Wen-Chung Lee),趙坤茂(Kun-Mao Chao),歐陽彥正(Yen-Jen Oyang) | |
dc.subject.keyword | 非小細胞肺癌,基因印記,微小核甘核酸,微陣列晶片,即時反轉錄聚合酶,連鎖反應,風險分數,決策樹, | zh_TW |
dc.subject.keyword | non-small-cell lung cancer,gene signature,microRNA,microarray,reverse- transcription polymerase chain reaction (RT-PCR),risk score,decision tree, | en |
dc.relation.page | 62 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-01-23 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 1.47 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。